Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis

BJU International

Volumn 108, Issue 8, 2011, Pages 1284-1285

  O'Donnell, Peter H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EDITORIAL; FATIGUE; GLOMERULUS FILTRATION RATE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; METASTASIS; PRIORITY JOURNAL; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; PYRROLES;

EID: 80053386365     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10179.x     Document Type: Editorial

References (12)

1. Khan G, Golshayan A, Elson P, et al,. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010; 21: 1618-22
2. Gupta S, Parsa V, Heilbrun L, et al,. Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). J Clin Oncol 2009; 27: abstract 5108
3. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
4. Miller DC, Schonlau M, Litwin MS, et al,. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008; 112: 511-20 (Pubitemid 351186192)
5. Josephs D, Hutson TE, Cowey CL, et al,. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011 [Epub ahead of print]. DOI: 10.1111/j.1464-410X.2010.09990.x
6. Rahman A, White RM,. Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol 2006; 24: 533-6 (Pubitemid 46630412)
7. van Erp NP, Gelderblom H, Guchelaar HJ,. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 692-706
8. Wilkinson GR,. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 475-90 (Pubitemid 27156933)
9. Khosravan R, Toh M, Garrett M, et al,. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50: 472-81
10. Dreisbach AW, Lertora JJ,. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-74
11. Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA,. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Clin Nephrol 2009; 72: 73-8
12. Demetri GD, van Oosterom AT, Garrett CR, et al,. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38 (Pubitemid 44528723)